Throughout 2024, Geron aggressively promoted the revenue prospects of imetelstat, sold as Rytelo, a telomerase inhibitor designed to combat malignant cell growth. However, the narrative shifted on February 26, 2025, when the company revealed that Rytelo’s sales had stalled. Executives cited seasonality, market competition, and the logistical burden of required patient monitoring as primary drivers for the flat performance.

This disclosure triggered an ongoing securities class action lawsuit, which alleges that leadership withheld critical information during the relevant period. Now, the firm led by former Louisiana Attorney General Charles C. Foti, Jr. is scrutinizing whether internal failures or misconduct occurred at the executive level. Shareholders or individuals with relevant insights into the company’s internal reporting practices are being urged to contact the firm to discuss potential legal recourse.